• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Ba Research International Receives Investment From Summit Partners

Posted on: Wednesday, 17 August 2005, 09:00 CDT

Ba Research International, a leading provider of generic analytical services for pharmaceutical companies worldwide, today announced it has received an investment from Summit Partners, a leading private equity and venture capital firm.

Founded in 1989, Ba Research is a pharmaceutical contract research organization (CRO) specializing in the analysis of biological samples for bioequivalence, bioavailability, and clinical trial studies. Previously known as Bioassay Laboratory, Inc., Ba Research has a customer base representing most of the top generic pharmaceutical companies and innovators worldwide.

Ba Research works with pharmaceutical drug developers facing the complicated, costly process of drug trials. As a CRO, Ba Research can more efficiently accomplish certain aspects of this process by working with traditional and generic pharmaceutical companies throughout all phases of their clinical trials to help determine proof-of-concept and drug efficacy.

"Our research chemists develop and validate analytical methods for pharmaceutical compounds and their metabolites with an emphasis on quality, accuracy and speed," said Paul Likhari, Chief Executive Officer and Chief Scientific Officer, Ba Research. "Since our founding, we have helped develop and lead the CRO sector through a focus on new method development and customer service."

"CROs are appealing outsourcing alternatives for pharmaceutical companies looking to expedite the time-to-market for their drugs, while also saving significant money on the actual performance of analytical and clinical work," said J.J. Kardwell, Vice President, Summit Partners, who has joined the company's Board of Directors along with John Carroll, General Partner, Summit Partners. "Ba Research is the leader in the analytical testing sector, and we are looking forward to supporting the team through the company's continued growth."

"Summit Partners' experience and resources will be invaluable to us as we continue to expand our business. This investment will enhance our ability to execute our growth strategy, which includes the continued introduction of innovative processes and the possible completion of strategic acquisitions," said Fiore Talarico, President, Ba Research.

Weil, Gotshal & Manges served as legal counsel for Summit Partners while Haynes & Boone represented Ba Research.

About Ba Research International

Ba Research International (www.baresearchinternational.com) is a full-service contract research organization specializing in analysis of biological samples for bioequivalence, bioavailability, and clinical trial studies for the pharmaceutical industry. Its state-of-the-art techniques provide methods that allow for processing of a large number of samples utilizing LC/MS/MS, HPLC and other analytical techniques. Studies are conducted under the company's standard operating procedures which meet Good Laboratory Practice requirements. Ba Research has developed and validated assay methods for more than 150 compounds. Founded in 1989, the company was previously known as Bioassay Laboratory, Inc.

About Summit Partners

Summit Partners (www.summitpartners.com) is a leading private equity and venture capital firm with offices in Boston, Palo Alto, and London. Founded in 1984, the firm has raised nearly $9 billion in capital in its private equity, venture capital, and subordinated debt funds. Summit has provided growth equity, recapitalization, and leveraged buyout financing to 270 companies, which have completed more than 100 public offerings, and in excess of 100 strategic mergers or sales. Summit Partners seeks outstanding management teams that have self-financed their companies to profitability and market leadership in a broad range of emerging growth industries, including healthcare and life sciences, technology, business and financial services, and industrial and consumer products. Previous Summit Partners investments in the healthcare and life sciences industry include AmeriPath, Clinical Pathology Laboratories, Clontech Laboratories, Hemophilia Resources of America, IMPAC Medical Systems, LogistiCare, NightHawk Radiology and Pediatrix Medical Group.

The business of Summit Partners in the U.K. is regulated by the Financial Services Authority. In the U.S., Summit Partners operates as an SEC registered investment adviser. This document is intended solely to provide information regarding Summit Partners' potential financing capabilities for prospective portfolio companies.

Source: Business Wire

More News in this Category